Centiva Capital’s Standard BioTools LAB Stock Holding History

Centiva Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,741	Closed	-$154K	–	1297
2020 Q4	$154K	Buy	+25,741	New	+$169K	0.01%	813

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Centiva Capital's LAB Position: Q1 2021 in Review

Centiva Capital sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 25,741 shares — an estimated $154K sold.

Centiva Capital first reported a position in LAB in Q4 2020 and held it in 1 quarter. The position peaked at $154K in Q4 2020. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

Centiva Capital reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
Centiva Capital sold 25,741 Standard BioTools shares in Q1 2021, an estimated $154K.
Centiva Capital first reported a position in Standard BioTools in Q4 2020 and held it in 1 quarter.
Centiva Capital's Standard BioTools position peaked at $154K in Q4 2020.
138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on Centiva Capital's 13F filing for Q1 2021, filed 17 May 2021.